Research programme: cancer vaccines - AEterna Zentaris

Drug Profile

Research programme: cancer vaccines - AEterna Zentaris

Alternative Names: AEZS-120; Bacterial cancer vaccines - AEterna Zentaris; Oral prostate cancer vaccine (AEZS-120) - AEterna Zentaris

Latest Information Update: 02 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AEterna Zentaris Inc
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Malignant melanoma; Prostate cancer

Most Recent Events

  • 29 Jul 2015 Aeterna Zentaris grants option to develop and commercialise oral allogeneic cancer vaccine technology, including AEZS 102, to German life sciences entreprenuers
  • 29 Jul 2015 AEterna Zentaris plans a phase I trial for Prostate cancer in Germany
  • 31 Dec 2013 Danish regulatory authorities approve the CTA for AEZS 120 in Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top